aluminum sulfate (alum)

Also Known As:

alum; alum, potassium; aluminium potassium sulfate 12-hydrate; aluminium potassium sulfate hydrate (1:1:2:12); aluminum hydrogen sulfate; aluminum potassium disulfate dodecahydrate; aluminum potassium sulfate; aluminum potassium sulfate dodecahydrate; potassium alum; potassium aluminum sulfate

Networked: 982 relevant articles (98 outcomes, 126 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfuric Acids: 4
      - Sulfates: 2753
        Alum Compounds: 1
        aluminum sulfate: 982
- Aluminum Compounds: 21
  - Alum Compounds: 1
    - aluminum sulfate: 982

Experts

1.	Ludvigsson, Johnny: 22 articles (05/2022 - 10/2008)
2.	Casas, Rosaura: 18 articles (05/2022 - 10/2008)
3.	Abe, Tatsuya: 8 articles (01/2022 - 11/2007)
4.	Hachiro, Yoshikazu: 8 articles (01/2022 - 11/2007)
5.	Kunimoto, Masao: 8 articles (01/2022 - 11/2007)
6.	Bernstein, David I: 8 articles (11/2020 - 11/2002)
7.	Axelsson, Stina: 7 articles (01/2017 - 10/2008)
8.	Bravo, Fernando J: 6 articles (11/2020 - 02/2003)
9.	Cadusseau, Josette: 6 articles (11/2015 - 04/2013)
10.	Chéramy, Mikael: 6 articles (07/2014 - 10/2008)

Related Diseases

1.	Infections 10/12/2012 - "Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge." 10/01/2009 - "This adjuvant activity of CLDC over alum may be beneficial for therapeutic vaccination in chronic HBV infection." 08/01/2003 - "Similarly, mice primed and boosted with the rSm23 in alum also did not develop significant levels of protection against challenge infection. " 04/01/2014 - "Immunization of BALB/c mice with alum-precipitated recombinant BmHsp70 conferred partial protection against subsequent challenge infection with the rodent parasite Litomosoides sigmodontis. " 06/06/2012 - "Systemic prophylactic immunization with AhpC/alum and mAhpC/alum conferred protection against infection in 55% and 77.3% of mice, respectively. "
2.	COVID-19 02/11/2021 - "AS03, CpG-Alum, AS37 and Alum groups conferred significant protection against SARS-CoV-2 infection in the pharynges, nares and in the bronchoalveolar lavage. " 01/01/2023 - "We investigated whether rBCG-ChD6 immunization followed by a boost with the recombinant nucleocapsid and spike chimera (rChimera), together with alum, provided protection against SARS-CoV-2 infection in K18-hACE2 mice. " 01/01/2021 - "Titres in all AS03 dose groups and the CpG/Alum 30 μg group were higher than were those recorded in a panel of convalescent serum samples from patients with COVID-19. " 01/01/2023 - "We show that vaccines adjuvanted with alum and BcfA, delivered through a heterologous prime-pull regimen, provide sustained protection against SARS-CoV-2 infection." 01/30/2023 - "Symptomatic COVID-19 was identified in 36 participants in the WIV04 group (9.9 [95% CI, 7.2-13.8] per 1000 person-years), 28 in the HB02 group (7.6 [95% CI, 5.2-11.0] per 1000 person-years), and 193 in the alum-only group (55.2 [95% CI, 47.9-63.5] per 1000 person-years), resulting in a vaccine efficacy of 82.0% (95% CI, 74.2-87.8%) for WIV04 and 86.3% (95% CI, 79.6-91.1%) for HB02. "
3.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/01/2022 - "To evaluate the long-term effect of intra-lymphatic administration of GAD-alum and a booster dose 2.5 years after the first intervention (DIAGNODE Extension study) in patients with recent-onset type 1 diabetes. " 05/01/2022 - "Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)." 10/30/2008 - "This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age. " 01/01/2022 - "Intralymphatic GAD-alum treatment in type 1 diabetes patients carrying HLA DR3DQ2 seems to be an attractive immune intervention." 01/01/2022 - "Intra-lymphatic GAD-alum treatment has shown encouraging results in Type 1 diabetes patients. "
4.	Neoplasms (Cancer) 12/09/2015 - "We report here an unexpected finding that injection of alum, the most widely used human adjuvant, into mice carrying H22 hepatocarcinoma resulted in a significant reduction of tumor growth with extended animal survival. " 01/01/2022 - "The improved efficacy of alum-anchored IFNs could be attributed to sustained pleiotropic effects on tumor cells, immune cells, and nonhematopoietic cells. " 01/01/2012 - "In our study, the results demonstrated that the mice immunized with tbFGF-alum-pVAX-8CpG produced a better tumor-suppression effect compared with the other groups, apart from the group treated with tbFGF-alum-CpG. " 01/01/2010 - "The Fe3O4 nanoparticles were compared with the common alum adjuvants for its ability to induce immunity to inhibit tumor growth rate by prophylactic and therapeutic studies. " 12/01/2017 - "However, alum hardly induces T helper 1 (Th1) immune responses that are required for anti-tumor immunity. "
5.	Human Influenza (Influenza) 12/21/2022 - "When applied to HA of H2N2 A/Japan/305/1957, the reoriented H2 HA (reoH2HA) on alum induced a stem-directed antibody response that cross-reacted with both group 1 and 2 influenza A HAs. " 09/01/2009 - "Mice were infected with influenza A virus and were sensitized intranasally with BSA/alum during the acute phase of influenza A viral infection. " 02/01/2017 - "Objective In this study, the effects of alum adjuvant on the efficiency and induction of immune response in inactive vaccines of Influenza and Newcastle are compared with those of ISA 70. " 12/01/2011 - "Preliminary results obtained in this study revealed that one year after a single subcutaneous immunisation with influenza A H3N2 virus in an oil-based carrier, Vaxcine(TM), outbreed mice produced a high immunoglobulin G response that lasted for up to one year and exhibited less variation in titre compared with the response of the control group treated with alum. " 11/01/2021 - "Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge."

Related Drugs and Biologics

1.	Vaccines
2.	Proteins (Proteins, Gene)
3.	Glutamate Decarboxylase (Decarboxylase, Glutamate)
4.	Neutralizing Antibodies
5.	Aluminum Hydroxide (Algeldrate)
6.	monophosphoryl lipid A
7.	Immunoglobulin G (IgG)
8.	Antibodies
9.	Antigens
10.	Tannic Acid

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics
3.	Urinary Diversion (Ileal Conduit)
4.	Oral Administration
5.	Microspheres (Microsphere)